NAMS

18.4105.64%
JJ

Johannes Jacob Pieter Kastelein

Founder, Chief Scientific Officer, Member of Executive Board & Director

Dr. Johannes Jacob Pieter Kastelein, also known as John, M.D., Ph.D., FESC, is Member of Scientific Advisory Board of Astria Therapeutics, Inc. Dr. Kastelein is Member of Cardiovascular Scientific Advisory Board of Veloxis Pharmaceuticals A/S. Dr. Kastelein is Co-Principal Investigator & Member of The Medical Advisory Board of AtheroNova Inc. Dr. Kastelein serves as Member of Clinical Advisory Board at Corsera Health, Inc. Dr. Kastelein joined the AtheroNova Inc. in 2012. Dr. Kastelein is Member of Synexus Scientific Advisory Board of Synexus Limited. Dr. Kastelein joined the Synexus Limited on December 06, 2011. Dr. Kastelein is Director of Symphony GenIsis Inc. Dr. Kastelein is Member of Clinical Advisory Board of Mazal Plant Pharmaceuticals Inc. Dr. Kastelein is Member of Atherosclerosis and Inflammation Advisory Board of Omthera Pharmaceuticals, Inc. Dr. Kastelein is Founder & Chairman of Scientific Advisory Board of Dezima Pharma B.V. Dr. Kastelein joined the Dezima Pharma B.V. in 2012. Dr. Kastelein is Member of Cardio Metabolic Advisory Board of Akcea Therapeutics, Inc. Dr. Kastelein is Senior Advisor of BioGeneration Ventures B.V. Dr. Kastelein was Advisor of BioGeneration Ventures B.V. Dr. Kastelein is Supervisory Board Member & Member of Scientific Advisory Board of NorthSea Therapeutics B.V. Dr. Kastelein was Member of Scientific Advisory Board of Inversago Pharma Inc until February 2025. Dr. Kastelein is Member of the Scientific Advisory Board of CinCor Pharma, Inc. Dr. Kastelein is Chief Medical Officer & Member of Advisory Board of Staten Biotechnology B.V. Dr. Kastelein is Member of Executive Board of NewAmsterdam Pharma Company N.V and serves as its Chief Scientific Officer and Director since January 1, 2020. Dr. Kastelein Founded NewAmsterdam Pharma Company N.V. Dr. Kastelein joined the NewAmsterdam Pharma Company N.V. in 2019. He serves as an Operating Partner at Forbion Capital Partners B.V. Dr. Kastelein was Scientific Advisor of Forbion Capital Partners B.V. Dr. Kastelein was Operating Partner of Forbion Capital Partners B.V. He advises Forbion on the cardiovascular and metabolic disease space and presents Forbion with investment opportunities in these fields. Dr. Kastelein was Director of VIVUS, Inc. Dr. Kastelein was employed at VIVUS, Inc. from July 19, 2013 to March 03, 2015. Dr. Kastelein was Member of Medical Advisory Board of Gemphire Therapeutics Inc. until August 2019. Dr. Kastelein was employed at Gemphire Therapeutics Inc. until August 2019. Dr. Kastelein was Member of Scientific Advisory Board of Matinas BioPharma Holdings, Inc. from December 06, 2018 to 2022. Dr. Kastelein was employed at Matinas BioPharma Holdings, Inc. from 2018 to 2022. Dr. Kastelein was Chairman of European Scientific Advisory Board of Amryt Pharmaceuticals Inc. Dr. Kastelein was Member of Atherosclerosis & Inflammation Advisory Board of Vascular Biogenics Ltd. Dr. Kastelein was Co-Founder of uniQure N.V. Dr. Kastelein was Member of Scientific Advisory Board of Anthera Pharmaceuticals, Inc. Dr. Kastelein was Member of Scientific Advisory Board of ABIONYX Pharma SA. Dr. Kastelein joined the ABIONYX Pharma SA on March 21, 2007. Dr. Kastelein was Member of Clinical Advisory Board of Genfit S.A. Dr. Kastelein was Member of Scientific Advisory Board of Lipid Sciences, Inc. Dr. Kastelein joined the Lipid Sciences, Inc. on February 12, 2007. He founded the Lipid Research Clinic at the Academic Medical Centre in 1989. In 2014, he was the Robert Levy Memorial Lecturer at American Heart Association Scientific Sessions. He serves as the Strategic Chairman of Genetics in Cardiovascular Disease at the Academic Medical Center of the University of Amsterdam. He was awarded an Established Investigatorship of the Dutch Heart Foundation. Dr Kastelein was the co-founder of Xenon Pharma, Uniqure, Dezima and NewAmsterdam Pharma, where he currently holds the position of Chief Science Officer. Dr. Kastelein was trained in Lipidology and Molecular Biology at the University of British Columbia, Vancouver; and was trained in Internal Medicine at the Academic Medical Centre from the University of Amsterdam. Dr. Kastelein has M.D. from University of Amsterdam in 1980.

Positions